News from the FDA/CDC

CDC data strengthen link between obesity and severe COVID


 

Officials have previously linked being overweight or obese to a greater risk for more severe COVID-19. A report today from the U.S. Centers for Disease Control and Prevention adds numbers and some nuance to the association.

Data from nearly 150,000 U.S. adults hospitalized with COVID-19 nationwide indicate that risk for more severe disease outcomes increases along with body mass index (BMI). The risk of COVID-19–related hospitalization and death associated with obesity was particularly high among people younger than 65.

“As clinicians develop care plans for COVID-19 patients, they should consider the risk for severe outcomes in patients with higher BMIs, especially for those with severe obesity,” the researchers note. They add that their findings suggest “progressively intensive management of COVID-19 might be needed for patients with more severe obesity.”

People with COVID-19 close to the border between a healthy and overweight BMI – from 23.7 kg/m2 to 25.9 kg/m2 – had the lowest risks for adverse outcomes.

The study was published online today in Morbidity and Mortality Weekly Report.

Greater need for critical care

The risk of ICU admission was particularly associated with severe obesity. For example, those with a BMI in the 40-44.9 kg/m2 category had a 6% increased risk, which jumped to 16% higher among those with a BMI of 45 or greater.

Compared to people with a healthy BMI, the need for invasive mechanical ventilation was 12% more likely among overweight adults with a BMI of 25-29.2. The risked jumped to 108% greater among the most obese people, those with a BMI of 45 or greater, lead CDC researcher Lyudmyla Kompaniyets, PhD, and colleagues reported.

Moreover, the risks for hospitalization and death increased in a dose-response relationship with obesity.

For example, risks of being hospitalized were 7% greater for adults with a BMI between 30 and 34.9 and climbed to 33% greater for those with a BMI of 45. Risks were calculated as adjusted relative risks compared with people with a healthy BMI between 18.5 and 24.9.

Interestingly, being underweight was associated with elevated risk for COVID-19 hospitalization as well. For example, people with a BMI of less than 18.5 had a 20% greater chance of admission vs. people in the healthy BMI range. Unknown underlying medical conditions or issues related to nutrition or immune function could be contributing factors, the researchers note.

Elevated risk of dying

The risk of death in adults with obesity ranged from 8% higher in the 30-34.9 range up to 61% greater for those with a BMI of 45.

Chronic inflammation or impaired lung function from excess weight are possible reasons that higher BMI imparts greater risk, the researchers note.

The CDC researchers evaluated 148,494 adults from 238 hospitals participating in PHD-SR database. Because the study was limited to people hospitalized with COVID-19, the findings may not apply to all adults with COVID-19.

Another potential limitation is that investigators were unable to calculate BMI for all patients in the database because about 28% of participating hospitals did not report height and weight.

The study authors had no relevant financial relationships to disclose.

A version of this article first appeared on Medscape.com.

Recommended Reading

Study clarifies who gets post–COVID-19 interstitial lung disease
Federal Practitioner
RECOVERY trial of COVID-19 treatments stops colchicine arm
Federal Practitioner
How to make resident mental health care stigma free
Federal Practitioner
CDC: Vaccinated people can gather indoors without masks 
Federal Practitioner
Five-day course of oral antiviral appears to stop SARS-CoV-2 in its tracks
Federal Practitioner
Potential COVID-19 variant surge looms over U.S.
Federal Practitioner
Federal Government Ramps Up COVID-19 Vaccination Programs
Federal Practitioner
Call to action on obesity amid COVID-19 pandemic
Federal Practitioner
Missed visits during pandemic cause ‘detrimental ripple effects’
Federal Practitioner
FDA authorizes first molecular at-home, OTC COVID-19 test
Federal Practitioner